Show simple item record

dc.contributor.authorLiang, Huan
dc.contributor.authorAcharya, Ganesh
dc.date.accessioned2021-04-19T08:04:15Z
dc.date.available2021-04-19T08:04:15Z
dc.date.issued2020-03-05
dc.description.abstractPregnancy is a state of partial immune suppression which makes pregnant women more vulnerable to viral infections, and the morbidity is higher even with seasonal influenza. Therefore, the COVID‐19 epidemic may have serious consequences for pregnant women. Although the vast majority of cases of COVID‐19 are currently in China, the risk of outward transmission appears to be significantly raising global concern. Human to human transmission of the virus is proven to occur,1, 2 perhaps even from asymptomatic patients,3, 4 and the mortality is substantial, especially among frail, elderly patients with comorbidities.5 Although there have been some criticisms surrounding suppression of early warnings, and slow initial response followed by heavy‐handed quarantine measures, as well as concerns expressed about the capacity to cope with the large number of patients, and shortage of protective equipment and in‐hospital infections leading to deaths among a substantial number of healthcare professionals,6, 7 China's effort to contain the disease and slow down its spread in China and world‐wide has been commendable. A large number of cases requiring hospitalization and intensive care is a serious burden even for affluent countries with well‐developed healthcare systems. However, the Chinese government, its health professionals, and the public, have set a new standard for handling the epidemic, and they have certainly contributed to reducing the potential risk of outbreak in neighboring countries with weaker healthcare systems. Furthermore, Chinese researchers and health professionals have generously shared their data, knowledge, experience and expertise that has helped to develop diagnostic tools, clinical management algorithms, set up clinical trials, and accelerate vaccine development. Clinical course and outcome of a substantial number of COVID‐19 patients have been reported, and recommendations regarding the care of such patients have been issued by several national health authorities across the world. However, the practices seem to vary considerably.en_US
dc.identifier.citationLiang H, Acharya G. Novel corona virus disease (COVID-19) in pregnancy: What clinical recommendations to follow?. Acta Obstetricia et Gynecologica Scandinavica. 2020;99(4):439-442en_US
dc.identifier.cristinIDFRIDAID 1813335
dc.identifier.doi10.1111/aogs.13836
dc.identifier.issn0001-6349
dc.identifier.issn1600-0412
dc.identifier.urihttps://hdl.handle.net/10037/20922
dc.language.isoengen_US
dc.publisherWileyen_US
dc.relation.journalActa Obstetricia et Gynecologica Scandinavica
dc.rights.accessRightsopenAccessen_US
dc.rights.holderCopyright 2020 The Author(s)en_US
dc.subjectVDP::Medical disciplines: 700en_US
dc.subjectVDP::Medisinske Fag: 700en_US
dc.titleNovel corona virus disease (COVID-19) in pregnancy: What clinical recommendations to follow?en_US
dc.type.versionpublishedVersionen_US
dc.typeJournal articleen_US
dc.typeTidsskriftartikkelen_US
dc.typePeer revieweden_US


File(s) in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record